Healthpeak Properties, Inc. $DOC Shares Acquired by KBC Group NV

KBC Group NV increased its stake in Healthpeak Properties, Inc. (NYSE:DOC) by 23.5% in the first quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 128,403 shares of the real estate investment trust’s stock after purchasing an additional 24,426 shares during the quarter. KBC Group NV’s holdings in Healthpeak Properties were worth $2,110,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also recently made changes to their positions in DOC. Norges Bank purchased a new stake in Healthpeak Properties during the fourth quarter worth about $153,550,000. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC grew its position in Healthpeak Properties by 694.6% during the third quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 8,016,692 shares of the real estate investment trust’s stock worth $153,520,000 after buying an additional 7,007,777 shares during the period. Bank of New York Mellon Corp increased its holdings in Healthpeak Properties by 60.3% in the first quarter. Bank of New York Mellon Corp now owns 15,456,420 shares of the real estate investment trust’s stock valued at $253,949,000 after buying an additional 5,815,189 shares in the last quarter. Fuller & Thaler Asset Management Inc. increased its holdings in Healthpeak Properties by 19.2% in the fourth quarter. Fuller & Thaler Asset Management Inc. now owns 29,648,260 shares of the real estate investment trust’s stock valued at $476,744,000 after buying an additional 4,776,056 shares in the last quarter. Finally, Millennium Management LLC lifted its position in shares of Healthpeak Properties by 235.3% during the 4th quarter. Millennium Management LLC now owns 3,512,223 shares of the real estate investment trust’s stock valued at $56,477,000 after acquiring an additional 2,464,612 shares during the period. Institutional investors and hedge funds own 93.57% of the company’s stock.

Healthpeak Properties Stock Performance

Healthpeak Properties stock opened at $22.29 on Friday. Healthpeak Properties, Inc. has a fifty-two week low of $15.70 and a fifty-two week high of $22.77. The company has a market capitalization of $15.37 billion, a price-to-earnings ratio of 69.67, a PEG ratio of 3.43 and a beta of 1.02. The stock has a fifty day moving average of $20.74 and a two-hundred day moving average of $18.45. The company has a debt-to-equity ratio of 1.15, a quick ratio of 2.96 and a current ratio of 2.96.

Healthpeak Properties (NYSE:DOC) last issued its quarterly earnings data on Tuesday, May 5th. The real estate investment trust reported $0.45 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.43 by $0.02. The business had revenue of $752.95 million for the quarter, compared to the consensus estimate of $694.59 million. Healthpeak Properties had a return on equity of 2.61% and a net margin of 7.73%.The business’s revenue was up 7.1% on a year-over-year basis. During the same period in the prior year, the business earned $0.46 earnings per share. Healthpeak Properties has set its FY 2026 guidance at 1.710-1.750 EPS. On average, analysts anticipate that Healthpeak Properties, Inc. will post 1.75 EPS for the current fiscal year.

Healthpeak Properties Announces Dividend

The company also recently announced a monthly dividend, which will be paid on Friday, September 25th. Investors of record on Monday, September 14th will be paid a $0.1017 dividend. The ex-dividend date of this dividend is Monday, September 14th. This represents a c) annualized dividend and a yield of 5.5%. Healthpeak Properties’s payout ratio is presently 381.25%.

Wall Street Analyst Weigh In

DOC has been the topic of several research analyst reports. Royal Bank Of Canada boosted their price target on Healthpeak Properties from $20.00 to $21.00 and gave the stock an “outperform” rating in a research note on Thursday, May 14th. UBS Group raised their price objective on Healthpeak Properties from $19.00 to $21.50 and gave the company a “neutral” rating in a research note on Wednesday, July 8th. JPMorgan Chase & Co. boosted their target price on Healthpeak Properties from $18.00 to $21.00 and gave the stock a “neutral” rating in a research report on Wednesday, June 24th. Morgan Stanley reissued an “equal weight” rating and issued a $22.00 target price (up from $20.00) on shares of Healthpeak Properties in a report on Thursday, June 11th. Finally, Barclays began coverage on Healthpeak Properties in a research report on Tuesday, July 7th. They issued an “equal weight” rating and a $23.00 price target for the company. Four investment analysts have rated the stock with a Buy rating and fifteen have given a Hold rating to the stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Hold” and an average target price of $20.62.

Insider Transactions at Healthpeak Properties

In other Healthpeak Properties news, insider Scott R. Bohn sold 10,989 shares of the company’s stock in a transaction dated Tuesday, May 12th. The shares were sold at an average price of $19.45, for a total value of $213,736.05. Following the transaction, the insider directly owned 7,636 shares in the company, valued at approximately $148,520.20. This represents a 59.00% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Company insiders own 0.23% of the company’s stock.

Healthpeak Properties Profile

Healthpeak Properties, Inc is a real estate investment trust (REIT) specializing in healthcare-related real estate. Headquartered in Irvine, California, the company owns, develops and acquires a diversified portfolio of properties that cater to the evolving needs of the healthcare industry. Its investments span life science research facilities, medical office buildings and senior housing communities, positioning Healthpeak as a key provider of specialized real estate assets.

Within its life science segment, Healthpeak develops and leases laboratory and research space to biotechnology, pharmaceutical and other life science companies.